Yazar "Muallaoglu, Sadik" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ N/A ]
    Öğe
    Gemcitabine plus Platinum Combination Chemotherapy in Patients with Metastatic Cancer who suffer from Severe and Irreversible Hepatic Impairment: A Single Center Experience
    (H G E Update Medical Publishing S A, 2014) Sezer, Ahmet; Sumbul, Ahmet Taner; Abali, Huseyin; Mertsoylu, Huseyin; Muallaoglu, Sadik; Kose, Fatih; Ozyilkan, Ozgur
    There is limited information on chemotherapeutic agent doses suitable for patients with metastatic cancer who suffer from and irreversible hepatic impairment and who could potentially benefit from chemotherapy and on their results. In this retrospective study, we aimed to share our center's experience of Gemcitabine + Platinum Combination chemotherapy in these patients. Data of 13 patients matching the criteria were analyzed. In our study the patients were treated with a dose of Gemcitabine + Platinum Combination, 50% of the original dose and the dose was increased gradually on the following days. Thirteen of one patient was given Gemcitabine & Carboplatin protocol and the others were given Gemcitabine & Cisplatin. In 42 chemotherapy cycles in total grade 3-4 thrombocytopenia occure after 7 cycles, grade 3-4 neutropenia was not observed While liver functions in 8 patients improved slightly, no change was observed in 2 patients and in 3 patients they deteriorated. Total survival period was calculate as 3.78 (95CI%: 0,17-7.54) months. As a consequence Gemcitabine + Platinum Combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment can be implemented when clinical benefits are expected.
  • [ N/A ]
    Öğe
    Lung tuberculosis causing false positivity on positron emission tomography
    (2013) Muallaoglu, Sadik; Ustun, I.; Kaya, Y.; Leblebici, I.
    [No abstract available]
  • Küçük Resim
    Öğe
    Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel
    (Springer, 2014) Sumbul, Ahmet Taner; Sezer, Ahmet; Abali, Huseyin; Kose, Fatih; Gultepe, Ilhami; Mertsoylu, Huseyin; Muallaoglu, Sadik
    The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response to treatment gradually increases in cancer patients. In this study, we aimed to investigate the effect of the pretreatment NLR and other factors related to the patient on predicting the outcome of docetaxel + prednisone chemotherapy in prostate cancer patients who become castration resistant. Thirty-three metastatic castration-resistant prostate cancer patients those who were treated between 2009 and 2013 were included in our study. All data of the patients, including pathological, clinical, radiological, biochemical and hematological data, were assessed retrospectively using our database system. The median progression-free survival (PFS) was determined as 23.9 months (range 0.36-118.7) with androgen suppression therapy and 9.5 months (range 1.7-39.4) with docetaxel + prednisone therapy. NLR was found to be correlated with only posttreatment psa levels. In the NLR a parts per thousand currency sign3 group, the PSA levels were statistically significantly lower than the other group (r = 0.002). Furthermore, the relationships between the clinical response and PFS and the other pretreatment parameters of the patients were evaluated in order to predict which group would respond better to docetaxel + prednisone therapy after becoming androgen resistant. No relationship was found between any of the parameters and the response to therapy. Although NLR was found effective in predicting the PSA response in docetaxel + prednisone therapy, neither NLR nor any other clinical parameter was found effective in predicting the outcome and the role of NLR in the future of CRPC is questionable.